UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling

Nature communications, 2016-06, Vol.7 (1), p.11267-11267, Article 11267

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

Nature medicine, 2017-04, Vol.23 (4), p.439-449

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

Journal of hepatology, 2016-06, Vol.64 (6), p.1365-1377

2016

Link zum Volltext

Verfügbarkeit prüfen

Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver

Hepatology (Baltimore, Md.), 2018-04, Vol.67 (4), p.1320-1338

2018

Link zum Volltext

Verfügbarkeit prüfen

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling

Nature communications, 2016-02, Vol.7 (1), p.10592-10592, Article 10592

2016

Link zum Volltext

Verfügbarkeit prüfen

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis

Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1492-1511

2017

Link zum Volltext

Verfügbarkeit prüfen

Regulator of G‐protein signalling 5 protects against atherosclerosis in apolipoprotein E‐deficient mice

British journal of pharmacology, 2015-12, Vol.172 (23), p.5676-5689

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury

Journal of hepatology, 2016-01, Vol.64 (1), p.146-159

2016

Link zum Volltext

Verfügbarkeit prüfen

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance

Hepatology (Baltimore, Md.), 2017-09, Vol.66 (3), p.834-854

2017

Link zum Volltext

Verfügbarkeit prüfen

Liver capsule: IRFs in hepatocytes: Pathophysiology

Hepatology (Baltimore, Md.), 2016-05, Vol.63 (5), p.1706-1706

2016

Link zum Volltext

Verfügbarkeit prüfen

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis

Journal of hepatology, 2016-07, Vol.65 (1), p.125-136

2016

Link zum Volltext

Verfügbarkeit prüfen

Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E–Deficient Mice

Hypertension (Dallas, Tex. 1979), 2017-03, Vol.69 (3), p.510-520

2017

Link zum Volltext

Verfügbarkeit prüfen

Interferon regulatory factor 9 is critical for neointima formation following vascular injury

Nature communications, 2014-10, Vol.5 (1), p.5160-5160, Article 5160

2014

Link zum Volltext

Verfügbarkeit prüfen

Interferon Regulatory Factor 8 Modulates Phenotypic Switching of Smooth Muscle Cells by Regulating the Activity of Myocardin

Molecular and Cellular Biology, 2014-02, Vol.34 (3), p.400-414

2014

Link zum Volltext

Verfügbarkeit prüfen

Caudodorsal approach combined with in situ split for laparoscopic right posterior sectionectomy

Surgical endoscopy, 2023-02, Vol.37 (2), p.1334-1341

2023

Link zum Volltext

Verfügbarkeit prüfen

Wang et al. reply

Nature medicine, 2018-06, Vol.24 (6), p.700-701

2018

Link zum Volltext

Verfügbarkeit prüfen

An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury

Nature medicine, 2018-01, Vol.24 (1), p.73-83

2018

Link zum Volltext

Verfügbarkeit prüfen

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis

Nature medicine, 2018-01, Vol.24 (1), p.84-94

2018

Link zum Volltext

Verfügbarkeit prüfen

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4

Nature medicine, 2017-06, Vol.23 (6), p.742-752

2017

Link zum Volltext

Verfügbarkeit prüfen

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis

Nature medicine, 2018-02, Vol.24 (2), p.213-223

2018

Link zum Volltext

Verfügbarkeit prüfen

Reprogramming Innate Immune Signaling in Cardiometabolic Disease

Hypertension (Dallas, Tex. 1979), 2017-05, Vol.69 (5), p.747-760

2017

Link zum Volltext

Verfügbarkeit prüfen

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity

Journal of hepatology, 2016-07, Vol.65 (1), p.113-124

2016

Link zum Volltext

Verfügbarkeit prüfen

Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β–Activated Kinase 1–Dependent Signaling Pathways

Hypertension (Dallas, Tex. 1979), 2017-02, Vol.69 (2), p.249-258

2017

Link zum Volltext

Verfügbarkeit prüfen

LITAF acts as a novel regulator for pathological cardiac hypertrophy

Journal of molecular and cellular cardiology, 2021-07, Vol.156, p.82-94

2021

Link zum Volltext

Verfügbarkeit prüfen

Mindin deficiency protects the liver against ischemia/reperfusion injury

Journal of hepatology, 2015-11, Vol.63 (5), p.1198-1211

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis

Regulator of G‐protein signalling 5 protects against atherosclerosis in apolipoprotein E‐deficient mice

Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance

Liver capsule: IRFs in hepatocytes: Pathophysiology

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis

Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E–Deficient Mice

Interferon regulatory factor 9 is critical for neointima formation following vascular injury

Interferon Regulatory Factor 8 Modulates Phenotypic Switching of Smooth Muscle Cells by Regulating the Activity of Myocardin

Caudodorsal approach combined with in situ split for laparoscopic right posterior sectionectomy

Wang et al. reply

An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis

Reprogramming Innate Immune Signaling in Cardiometabolic Disease

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity

Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β–Activated Kinase 1–Dependent Signaling Pathways

LITAF acts as a novel regulator for pathological cardiac hypertrophy

Mindin deficiency protects the liver against ischemia/reperfusion injury

Suchergebnisse filtern